Cryptococcal Meningitis Treatment Granted QIDP Status
Viamet Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129 for the treatment of cryptococcal meningitis
In preclinical studies, VT-1129 exhibited potent activity against clinical Cryptococcus isolates, including highly fluconazole-resistant strains. In September 2014, the FDA had granted VT-1129 Orphan Drug designation.
VT-1129 is a potent and highly selective inhibitor of fungal CYP51 enzyme in Cryptococcus neoformans. CYP51, a metalloenzyme essential for fungal proliferation and survival, is the target of several marketed antifungal therapies.
For more information visit Viamet.com.